Sudeep Pharma

    SUDEEPPHRM
    Chemicals
    ₹1,202.20
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹13,579 Cr

    P/E
    71.35
    Day range
    ₹1,175.30 – ₹1,227.80
    52-week range
    ₹524.05 – ₹1,378.00
    Volume
    1.03 L
    Open
    ₹1,210.30
    Prev close
    ₹1,217.50

    Latest results · Q2 FY27(consolidated)Revenue ₹197 Cr+20.9%Profit ₹52 Cr+10.8%Margin 26.3%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 57 / 100

    Factor percentiles

    Value19
    Quality70
    Momentum93
    Low volatility47

    Derived metrics

    Earn. yield
    1.4%
    Graham no.
    ₹177.14
    vs Graham
    -85.3%
    ROE ÷ P/B
    1.8%
    Magic Formula
    #340
    Piotroski
    3/6
    FCF yield
    -0.4%
    PEG
    6.72

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 44 in Chemicals
    Largest Chemicals companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Solar IndustriesSOLARINDS₹1.68 L Cr74.0422.1932.5%38.0%29.0%0.23+69.0%
    Pidilite IndustriesPIDILITIND₹1.56 L Cr58.1214.0524.0%31.0%20.0%0.03+20.9%
    SRF LtdSRF₹72,471 Cr31.754.8013.8%15.0%19.0%0.35+34.7%
    Linde IndiaLINDEINDIA₹58,548 Cr118.4613.4213.6%18.0%32.0%0.23+12.3%
    Coromandel InternationalCOROMANDEL₹57,701 Cr37.014.3016.1%22.0%9.0%0.12+6.6%
    Gujarat FluorochemicalsFLUOROCHEM₹52,952 Cr78.396.177.6%10.0%27.0%0.28+45.5%
    Navin Fluorine InternationalNAVINFLUOR₹52,759 Cr57.9511.3720.1%21.0%34.0%0.28+57.1%
    Sudeep PharmaSUDEEPPHRM₹13,579 Cr71.3514.3625.3%28.0%37.0%0.20+20.9%
    Sector median₹13,505 Cr31.752.869.9%12.0%15.7%0.27+21.5%

    Sector as classified in the tracked universe; medians use every tracked Chemicals company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 3h ago

    Headlines about Sudeep Pharma from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    73.1
    Price / Book
    14.18
    ROE (FY26)
    25.3%
    ROCE (latest year)
    28%
    Dividend yield
    0.12%

    Moving averages (NSE)

    20-day
    ₹1,116.33
    Price above
    50-day
    ₹1,137.62
    Price above
    200-day
    ₹858.82
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +14.4%
    Profit 3Y CAGR
    +41.1%
    Revenue YoY (Sep 2026)
    +20.9%
    Profit YoY (Sep 2026)
    +10.6%
    Operating margin
    37.0%
    Net margin
    26.4%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr50 Cr100 Cr150 Cr200 Cr
    • Revenue
    • Net profit

    Operating margin

    Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 20260%25%50%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • Public
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-400 Cr-200 Cr0 Cr200 Cr400 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY21FY22FY23FY24FY25FY260%20%40%60%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr250 Cr500 Cr750 Cr1K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x0.5x1x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales149116158125163172182158197
    Expenses85769981107112120103123
    Operating Profit633959445560635573
    OPM %43%34%37%35%34%35%34%35%37%
    Other Income2245107656
    Interest112221223
    Depreciation333344445
    Profit before tax623858446062635471
    Tax %21%24%24%29%21%23%23%25%27%
    Net Profit492944314748494152
    EPS in Rs₹4.38₹2.58₹3.97₹2.77₹4.11₹4.20₹4.33₹3.59₹4.56

    From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days129

    +35 days since Mar 2021

    Inventory Days356

    +277 days since Mar 2021

    Days Payable113

    +34 days since Mar 2021

    Cash Conversion Cycle372

    +279 days since Mar 2021

    Working Capital Days175

    +162 days since Mar 2021

    Strengths, risks & growth

    Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries. [1]

    Strengths

    • Company has delivered good profit growth of 39.0% CAGR over last 5 years
    • Company has a good return on equity (ROE) track record: 3 Years ROE 31.8%

    Risks

    • Stock is trading at 14.4 times its book value

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +24%
    3 Years
    +14%
    TTM
    +27%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +39%
    3 Years
    +40%
    TTM
    +26%

    Return on Equity

    10 Years
    —
    5 Years
    +32%
    3 Years
    +32%
    Last Year
    +25%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter76.16%76.16%76.16%76.16%0.00 pp
    FII1.67%1.55%1.81%2.93%+1.12 pp
    DII17.59%18.11%15.64%14.06%-1.58 pp
    Public4.57%4.18%6.39%6.87%+0.48 pp

    Filed with NSE for Sept 2026: promoters 76.15%, public 23.85%

    Analysts & fund holdings

    0%
    0% recommend buy
    2 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E71.3 vs 45.1
    Sector P/B6.03

    Who holds the shares, quarter by quarter

    Mutual funds 7.43% (+1.96 pp)
    Jun 25
    Nov 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters76.2%
    • Foreign institutions2.9%
    • Mutual funds7.4%
    • Insurance1.0%
    • Other domestic institutions5.6%
    • Retail4.1%
    • Others2.8%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Axis Small Cap Fund1.55%0.73%+0.14 pp
    SBI Healthcare Opp Fund1.02%2.39%+0.18 pp
    HDFC Manufacturing Fund0.68%0.91%+0.22 pp
    SBI MNC Fund0.53%1.20%+0.26 pp
    SBI Comma Fund0.53%6.35%+1.24 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Avg
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 239 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    48.1%
    Downside volatility
    43.1%
    Worst 5% of days
    5.1%
    Average of that tail
    5.7%
    Max drawdown (1Y)
    31.5%
    Below its peak
    10.6%

    Against the market

    Beta vs Nifty 50
    0.79
    Correlation
    0.24
    Relative strength (3M)
    +5.3%
    ATR (14)
    4.9%

    Return

    Return 1M
    +20.1%
    Return 3M
    +9.1%
    Return 6M
    +85.2%
    Return 1Y
    —
    vs 200-day average
    +40.0%

    Momentum

    RSI (14)
    59.3
    MACD histogram
    11.41
    Stochastic %K
    73.2
    ADX (14)
    27.0
    +DI / −DI
    22.7 / 15.6
    Money flow index
    74.9

    Participation

    Delivery (20d avg)
    45.5%
    vs its 60-day baseline
    -3.9 pts
    Volume vs 20-day
    -0.7σ
    Close vs day's VWAP
    +0.3%
    52-week position
    83 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    3 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — failed
    Free cash flow
    -₹49 Cr
    FCF yield
    -0.4%
    Net debt
    ₹136 Cr
    Net debt / equity
    0.14
    EV / sales
    19.57
    PEG
    6.72
    Revenue CAGR
    20.9%
    Profit CAGR
    10.8%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹1.50

      Dividend - Rs 1.50 Per Share

      23 Jul 2026
      ex-date

    Documents

    Annual reports

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 29 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Sudeep Pharma: common questions

    Answered from the figures on this page.

    Sudeep Pharma last traded at ₹1,202.20 (NSE, as of 18 Nov 2026). The last session moved it down 1.26%.

    Sudeep Pharma is valued at about ₹13,579 crore (NSE, as of 18 Nov 2026).

    Sudeep Pharma trades at a price-to-earnings ratio of 71.35 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Sudeep Pharma has traded between ₹524.05 and ₹1,378.00 over the past 52 weeks, to 18 Nov 2026. It is currently 79% of the way up that range.

    Sudeep Pharma (SUDEEPPHRM) is classified under Chemicals on this site's screener.